J
James W. Crow
Researcher at Research Triangle Park
Publications - 23
Citations - 7173
James W. Crow is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Pulmonary hypertension & Prostacyclin. The author has an hindex of 18, co-authored 23 publications receiving 6920 citations. Previous affiliations of James W. Crow include GlaxoSmithKline & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal ArticleDOI
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Gérald Simonneau,Robyn J. Barst,Nazzareno Galiè,Robert Naeije,Stuart Rich,Robert C. Bourge,Anne Keogh,Ronald J. Oudiz,Adaani E. Frost,Shelmer D. Blackburn,James W. Crow,Lewis J. Rubin +11 more
TL;DR: Chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension and significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics.
Journal ArticleDOI
Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension
Ronald J. Raymond,Alan L. Hinderliter,Park W. Willis,David D. Ralph,Edgar J. Caldwell,William Williams,Neil A. Ettinger,Nicholas S. Hill,Warren R. Summer,Bennett De Boisblanc,Todd A. Schwartz,Gary G. Koch,Linda M. Clayton,Maria M. Jöbsis,James W. Crow,Walker Long +15 more
TL;DR: Pericardial effusion, right atrial enlargement and septal displacement are echocardiographic abnormalities that reflect the severity of right heart failure and predict adverse outcomes in patients with severe PPH.
Journal ArticleDOI
Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial
Lewis J. Rubin,Jessica Mendoza,Michele Hood,Michael D. McGoon,Robyn J. Barst,William Williams,Jane Hall Diehl,James W. Crow,Walker Long +8 more
TL;DR: In this article, the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary pulmonary hypertension was evaluated in a randomized trial with 8-week treatment periods and nonrandomized treatment for up to 18 months.
Journal Article
Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Lewis J. Rubin,Jessica Mendoza,Michele Hood,Michael D. McGoon,Robyn J. Barst,William Williams,Jane Hall Diehl,James W. Crow,Walker Long +8 more
TL;DR: Prostacyclin produces substantial and sustained hemodynamic and symptomatic responses in severe primary pulmonary hypertension and may be useful in the management of some patients with this disease.